Cargando…
Early antiviral treatment in outpatients with COVID-19 (FLARE): a structured summary of a study protocol for a randomised controlled trial
OBJECTIVES: The objective of this trial is to assess whether early antiviral therapy in outpatients with COVID-19 with either favipiravir plus lopinavir/ritonavir, lopinavir/ritonavir alone, or favipiravir alone, is associated with a decrease in viral load of SARS-CoV-2 compared with placebo. TRIAL...
Autores principales: | Brown, Li-An K., Freemantle, Nick, Breuer, Judy, Dehbi, Hakim-Moulay, Chowdhury, Kashfia, Jones, Gemma, Ikeji, Felicia, Ndoutoumou, Amalia, Santhirakumar, Krishneya, Longley, Nicky, Checkley, Anna M., Standing, Joseph F., Lowe, David M. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7938371/ https://www.ncbi.nlm.nih.gov/pubmed/33685502 http://dx.doi.org/10.1186/s13063-021-05139-2 |
Ejemplares similares
-
Favipiravir, lopinavir-ritonavir, or combination therapy (FLARE): A randomised, double-blind, 2 × 2 factorial placebo-controlled trial of early antiviral therapy in COVID-19
por: Lowe, David M., et al.
Publicado: (2022) -
Belimumab after B cell depletion therapy in patients with systemic lupus erythematosus (BEAT Lupus) protocol: a prospective multicentre, double-blind, randomised, placebo-controlled, 52-week phase II clinical trial
por: Jones, Alexis, et al.
Publicado: (2019) -
Sample size calculation in randomised phase II selection trials using a margin of practical equivalence
por: Dehbi, Hakim-Moulay, et al.
Publicado: (2020) -
Life expectancy difference and life expectancy ratio: two measures of treatment effects in randomised trials with non-proportional hazards
por: Dehbi, Hakim-Moulay, et al.
Publicado: (2017) -
Sample size calculation for randomized selection trials with a time‐to‐event endpoint and a margin of practical equivalence
por: Dehbi, Hakim‐Moulay, et al.
Publicado: (2022)